Location · San Antonio, TX
Clinical trials in San Antonio, TX
347 recruiting studies have a site in the San Antonio area, and 68 of them accept healthy volunteers. The area includes New Braunfels, Schertz, Boerne, Live Oak, Universal City and nearby cities.
347 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
More recruiting studies (pay not posted)
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Hoffmann-La Roche
- Location
- Orange, CA + 9 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
GlaxoSmithKline
- Location
- Sheffield, AL + 50 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
Elion Therapeutics, Inc.
- Location
- Birmingham, AL + 9 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Amgen
- Location
- Anniston, AL + 69 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Merck Sharp & Dohme LLC
- Location
- Bristol, CT + 11 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 2
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
Retension Pharmaceuticals. Inc.
- Location
- Alexander City, AL + 31 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2/Phase 3
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
Centessa Pharmaceuticals (UK) Limited
- Location
- Birmingham, AL + 19 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 1/Phase 2
A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)
Prime Medicine, Inc.
- Location
- San Antonio, TX
- Eligibility basics
- Ages 12+
- Recruiting
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Shockwave Medical, Inc.
- Location
- Phoenix, AZ + 66 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Janssen Research & Development, LLC
- Location
- Tucson, AZ + 44 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
- Location
- Tucson, AZ + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Takeda
- Location
- Bryant, AR + 20 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Ascendis Pharma A/S
- Location
- Palo Alto, CA + 21 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk A/S
- Location
- Escondido, CA + 26 other US sites
- Eligibility basics
- Ages 8–18
- Recruiting
Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis
Polyrizon Ltd.
- Location
- Normal, IL + 3 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
GlaxoSmithKline
- Location
- Little Rock, AR + 10 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
GlaxoSmithKline
- Location
- Little Rock, AR + 15 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
GlaxoSmithKline
- Location
- Topeka, KS + 2 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Post-Market Study to Assess iTind Safety in Comparison to UroLift
Olympus Corporation of the Americas
- Location
- Phoenix, AZ + 10 other US sites
- Eligibility basics
- Ages 50+ · Men only
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.
- Location
- Anaheim, CA + 17 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
Intra-Cellular Therapies, Inc.
- Location
- Anaheim, CA + 22 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Irvine, CA + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Irvine, CA + 17 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
Genentech, Inc.
- Location
- Beverly Hills, CA + 23 other US sites
- Eligibility basics
- Ages 18+